Immunicum: On the right track to produce significant topline results during 2019
Research Note
2019-02-18
11:32
The Q4 2018 earnings report last week was largely uneventful, in line with our expectations. All the 2019 catalyst remain on track, where the most important is the topline results from the MERECA trial, expected in Q3 2019. We reiterate our base case fair value of SEK 16.
KP
Klas Palin
Disclosures and disclaimers